VIR
Vir Biotechnology, Inc.Company with tickers: VIR
CIK
1706431
CUSIP
92764N102
Shares Outstanding
168,651,974
Website
https://www.vir.bio
Investor Relations
https://investors.vir.bio/overview/default.aspx
13F Activity (30d)
66 filings
63 filers
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
No Compensation Data
No Summary Compensation Table has been imported from this company's proxy statements yet.
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Timothy Coughlin | Chair of the Audit Committee of the Board | Appointed | 2026-06-10 |
| Timothy Coughlin | Class III director | Appointed | 2026-06-10 |
| Saira Ramasastry, M.S., M.Phil. | Chair of the Company's Audit Committee | Resigned | 2026-05-28 |